Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
Kingchem
301509
5
Hunan Er-kang Pharmaceutical
300267
(Q3)Mar 31, 2025 | (FY)Dec 31, 2024 | (Q9)Sep 30, 2024 | (Q6)Jun 30, 2024 | (Q3)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q9)Sep 30, 2023 | (FY)Dec 31, 2022 | (Q9)Sep 30, 2022 | (Q6)Jun 30, 2022 | |
---|---|---|---|---|---|---|---|---|---|---|
Total operating revenue | 23.81%167.91M | 23.20%681.7M | 20.71%455.95M | 286.86M | 135.61M | 12.64%553.31M | 14.70%377.72M | 8.20%491.23M | 9.42%329.31M | 204.2M |
Operating revenue | 23.81%167.91M | 23.20%681.7M | 20.71%455.95M | --286.86M | --135.61M | 12.64%553.31M | 14.70%377.72M | 8.20%491.23M | 9.42%329.31M | --204.2M |
Other operating revenue | ---- | 6.24%11.63M | ---- | --5.45M | ---- | 15.94%10.95M | ---- | -35.61%9.44M | ---- | --5.18M |
Total operating cost | 25.44%135.41M | 19.01%543.68M | 233.98M | 107.95M | 13.82%456.85M | 1.58%401.39M | 173.28M | |||
Operating cost | 28.77%114.62M | 20.33%466.9M | 20.57%313.4M | --195.48M | --89.01M | 10.71%388M | 9.77%259.92M | 11.53%350.45M | 11.09%236.8M | --146.58M |
Operating tax surcharges | 13.23%1.72M | 43.75%7.07M | ---- | --2.95M | --1.52M | 123.22%4.92M | ---- | -26.23%2.2M | ---- | --629.12K |
Operating expense | 3.97%3.97M | 7.90%15.85M | ---- | --8.23M | --3.82M | 15.95%14.69M | ---- | -7.55%12.67M | ---- | --6.66M |
Administration expense | 7.91%11.55M | 11.14%42.79M | ---- | --22.2M | --10.71M | 16.32%38.5M | ---- | -9.53%33.1M | ---- | --17.75M |
Financial expense | 22.47%-2.58M | -15.70%-16.46M | ---- | ---8.3M | ---3.33M | 34.94%-14.23M | ---- | -576.44%-21.87M | ---- | ---9.25M |
-Interest expense (Financial expense) | -25.00%975.58K | 3.49%4.8M | ---- | --2.55M | --1.3M | 7.68%4.63M | ---- | -4.51%4.3M | ---- | --3.25M |
-Interest Income (Financial expense) | 4.93%-4.04M | -12.74%-16.6M | ---- | ---8.93M | ---4.25M | -103.38%-14.73M | ---- | -64.88%-7.24M | ---- | ---1.94M |
Research and development | -1.41%6.13M | 10.30%27.54M | ---- | --13.42M | --6.22M | 0.54%24.97M | ---- | 7.77%24.83M | ---- | --10.91M |
Credit Impairment Loss | 18.95%2.32M | -153.96%-5.47M | ---- | --775.04K | --1.95M | 19.43%-2.15M | ---- | -7,555.92%-2.67M | ---- | --986.78K |
Asset Impairment Loss | 48.65%-1.23M | -145.92%-13.73M | ---- | ---6.52M | ---2.4M | 33.28%-5.58M | ---- | -223.89%-8.37M | ---- | ---4.71M |
Other net revenue | 1,803.94%11.85M | -637.68%-14.47M | 0 | -4.15M | 622.58K | 48.42%-1.96M | 0 | -102.19%-3.8M | 0 | -2.2M |
Asset deal income | 28.65%-23.21K | -177.94%-714.31K | ---- | ---545.73K | ---32.52K | 16.81%916.54K | ---- | 147.82%784.63K | ---- | ---- |
Other revenue | 877.36%10.79M | 11.88%5.43M | ---- | --2.14M | --1.1M | -24.71%4.85M | ---- | -38.07%6.45M | ---- | --1.53M |
Operating profit | 56.77%44.35M | 30.73%123.54M | 5.43%70.75M | 48.74M | 28.29M | 9.83%94.5M | 11.98%67.1M | -62.97%86.04M | -70.63%59.92M | 28.73M |
Add:Non operating Income | 684.93%53.52K | 229.53%160.03K | ---- | --33.19K | --6.82K | -16.40%48.56K | ---- | -43.80%58.09K | ---- | --17.71K |
Less:Non operating expense | -93.36%44.24K | 405.50%1.26M | ---- | --660.02K | --666.18K | 1,050.98%250.1K | ---- | -94.50%21.73K | ---- | --15.78K |
Total profit | 60.54%44.36M | 29.84%122.44M | 4.65%70.13M | 48.11M | 27.63M | 9.55%94.3M | 11.78%67.01M | -62.91%86.08M | -70.58%59.95M | 28.73M |
Less:Income tax cost | 34.98%5.84M | 29.48%15.1M | ---- | --6.47M | --4.32M | 25.97%11.66M | ---- | -71.05%9.26M | ---- | --2.89M |
Net profit | 65.29%38.52M | 29.89%107.34M | 4.02%61.06M | 41.64M | 23.3M | 7.57%82.64M | 10.53%58.7M | -61.61%76.82M | -69.61%53.11M | 25.84M |
Net profit from continuing operation | ---- | 29.89%107.34M | ---- | --41.64M | ---- | 7.57%82.64M | ---- | -61.61%76.82M | ---- | --25.84M |
Net profit of parent company owners | 65.29%38.52M | 29.89%107.34M | ---- | --41.64M | --23.3M | 7.57%82.64M | ---- | -61.61%76.82M | 77.39%49.88M | --25.84M |
Earning per share | ||||||||||
Basic earning per share | 83.33%0.11 | 30.43%0.3 | ---- | --0.12 | --0.06 | 9.52%0.23 | ---- | -61.82%0.21 | ---- | --0.07 |
Diluted earning per share | 83.33%0.11 | 30.43%0.3 | ---- | --0.12 | --0.06 | 9.52%0.23 | ---- | -61.82%0.21 | ---- | --0.07 |
Other composite income | ||||||||||
Total composite income | 65.29%38.52M | 29.89%107.34M | 41.64M | 23.3M | 7.57%82.64M | -61.61%76.82M | 25.84M | |||
Total composite income of parent company owners | 65.29%38.52M | 29.89%107.34M | ---- | --41.64M | --23.3M | 7.57%82.64M | ---- | -61.61%76.82M | ---- | --25.84M |
Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
Accounting Standards | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) |
Audit Opinions | -- | Unqualified opinion | -- | -- | -- | Unqualified opinion | -- | Unqualified opinion | -- | -- |
Auditor | -- | Zhonghui Certified Public Accountants (Special General Partnership) | -- | -- | -- | Zhonghui Certified Public Accountants (Special General Partnership) | -- | Zhonghui Certified Public Accountants (Special General Partnership) | -- | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.